ERBB2 and breast carcinoma: Additionally, an increased proportion of breast cancer with Her2/neu overexpression was found in the group with high expression of CD105 compared to the group with low expression of this marker (27.78% vs. 11.76%, respectively, p = 0.003) (Figures 5A,B).